NovaBay Highlights Data From Phase 2 UCBE Study.

NovaBay Pharmaceuticals, Inc., an advanced clinical-stage biopharmaceutical company developing topical antimicrobial products, today released a video of its Analyst and Investor Event which was held on September 17th in New York City.

At the event, Dr. Ron Najafi, Chairman and Chief Executive Officer of NovaBay, provided an overview of the company’s goals and milestones reached. NovaBay senior management team along with the clinicians involved in the study and key opinion leaders presented the data from NovaBay’s phase 2 clinical study of auriclosene to reduce urinary catheter blockage and encrustation (UCBE) of indwelling urinary catheters.

UCBE Analyst Day Video

NovaBay Highlights Data from Phase 2 UCBE Study. Video can be viewed here. Highlighted in the video are:
  • Ron Najafi, Ph.D., Chairman and CEO, NovaBay
  • Keith R. Bley, Ph.D., Senior Vice President of Product Development, NovaBay;
  • Todd Linsenmeyer, M.D., Director of Urology at the Kessler Institute for Rehabilitative Medicine in West Orange, NJ and the principal investigator in NovaBay’s phase 2 UCBE study;
  • V. Spencer Long, M.D., Urologist at J.C. Blair Memorial Hospital in Huntingdon, PA; and;
  • Mary Wilde, Ph.D., R.N., Associate Professor of Nursing at the University of Rochester Medical Center.

Press release, patient and physician video, presentation, and video from the UCBE analyst and investor event are available on NovaBay’s website.

Due to spinal cord injuries, multiple sclerosis, strokes, or neurogenic bladder conditions, an estimated 100,000 patients in the U.S. have indwelling catheters and episodically suffer from blockage and encrustation. In these patients, catheters repeatedly become colonized with bacteria and bacterial biofilm, which may produce localized crystal deposits that may build up and block the catheter. Urinary catheter blockages pose health risks to these patients and are a contributor to medical emergencies, increased health care costs and decreased quality of life.

If you liked this article you might like

3 Biotech Stocks Under $10 to Trade for Big Breakouts

Novabay Pharmaceuticals (NBY) Stock Spikes After FDA Approves Disinfection System

Insider Trading Alert - NBY, WPX And KTOS Traded By Insiders

Insider Trading Alert - EVTC, CRM And NBY Traded By Insiders

Insider Trading Alert - CGIX, NBY And BIOA Traded By Insiders